Navigation Links
Human Trial for Universal Influenza Vaccine Underway

A universal influenza vaccine that has been pioneered by researchers from VIB and Ghent University is being tested for the first time on humans by the British-American biotech company Acambis .

This vaccine is intended to provide protection against all A strains of the virus that causes human influenza, including pandemic strains.

In the 1990s, VIB researchers connected to Ghent University, under the direction of Prof. Emeritus Walter Fiers, invented a universal flu vaccine. One protein on the surface of the influenza virus, the so-called M2 protein, remains unchanged in all human flu viruses known, including the strains that caused the pandemics in the last century.

On the basis of the M2-protein they developed a vaccine and successfully tested it on mice and other laboratory animals: the M2 vaccine provided total protection against A strains of flu, without side effects. Furthermore, this universal influenza vaccine is the first example of a vaccine inducing a protective immune response that normally does not occur in nature, for example following infection by a virus or a bacterium.

At the moment, Phase I clinical trials on humans are underway - that is, the candidate vaccine is being administered to a small group of healthy people in order to verify the safety of the product and to provide an initial insight into the vaccines effect on the human immune system.

Xavier Saelens, Prof. Emeritus Willy Min Jou, and Prof. Emeritus Walter Fiers are leading the fundamental research forward with respect to protection against influenza epidemics and pandemics. This involves, amongst other, supporting research required for the planned Phase II and III clinical trials. Through their collaboration with Acambis, they hope that annual flu vaccines can ultimately be replaced by the new, universal flu vaccine.

The goal for this vaccine is that two inoculations would suffice to protect people a gainst all A strains of flu.


'"/>




Related medicine news :

1. Human Genome Project Achieves Technological Triumph
2. First Vaccine Designed for Africa Cleared for Testing in Humans
3. Human gene number increases
4. Scientists found ancient Human Germ Killer
5. New standards for Human Research Safety
6. Human wasting disease linked to a gene
7. The Human Mad Cow Case
8. Human Growth Hormone Found To be Dangerous For Human Use
9. Human Antibody That Can Block SARS
10. Human immunity system can battle HIV.
11. Two New Human Papilloma virus (HPV) vaccines to prevent cervical cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... Iowa (PRWEB) , ... April 26, 2017 , ... ... DuPont Pioneer today launched a unique website ( CRISPRCas.pioneer.com ) that demonstrates how ... and help farmers produce more and better food, with fewer resources. It highlights ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... announces Mirroring360 Pro . This new addition to the Mirroring360 product family ... education and business. , Mirroring360 Pro enables educators, business professionals and individuals to ...
(Date:4/25/2017)... Boulder, CO (PRWEB) , ... April 25, 2017 ... ... Law and Liberty attempts to compare student test score performance for the 2015-16 ... one of the state’s voucher programs. Though it highlights important patterns in student ...
(Date:4/25/2017)... ... April 25, 2017 , ... As Spring reignites ... defects research related to Zika virus during pregnancy, as well as other prenatal ... important science. , The Teratology Society is an international and ...
(Date:4/25/2017)... Ariz. (PRWEB) , ... April 25, 2017 , ... Emergency ... latest book of the Outlier Leadership Series, Outliers in Writing, set to publish in ... Professor of Emergency Medicine at the University of Arizona College of Medicine. He also ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... , April 24, 2017 Solentim, the ... announced the addition of a major new product ... Plate Seeding,). The VIPS has been developed for ... well microplates as part of the process to ... a simple and more reliable solution when compared ...
(Date:4/20/2017)... Research and Markets has announced the addition ... Addressing Production Complexities Through Risk Management and Quality by ... ... Market Prospects: Overcoming Production Complexities Through Risk Management and ... current trends in the global biosimilars market, with a ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
Breaking Medicine Technology: